Pharmacogenomic technologies: A necessary "luxury" for better global public health?

Globalization and Health

Volumn 7, Issue , 2011, Pages

  Olivier, Catherine ^a   Williams Jones, Bryn ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Developing World Populations; Global; Health Innovations; Inequity; Luxury; Pharmacogenomic Technologiesdrug Development; Public Health; University Of Toronto Joint Centre For Bioethics Criteria

Indexed keywords

DEVELOPING WORLD; DISEASE CONTROL; DISEASE TREATMENT; DRUG DEVELOPMENT; FEASIBILITY STUDY; GENOMICS; GLOBAL PERSPECTIVE; HEALTH CARE; HEALTH IMPACT; HEALTH SERVICES; INFECTIOUS DISEASE; INNOVATION; MEDICINE; PUBLIC HEALTH; RESEARCH AND DEVELOPMENT; RESEARCH INSTITUTION; TECHNOLOGICAL DEVELOPMENT;

ARTICLE; BIOETHICS; HEALTH CARE; PHARMACOGENOMICS; PRIORITY JOURNAL; TECHNOLOGY;

CANADA; ONTARIO [CANADA]; TORONTO;

EID: 80052021468     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-7-30     Document Type: Article

References (102)

1. Kemp S. Perceiving luxury and necessity. Journal of Economic Psychology 1998, 19(5):591-606.
2. Whitehead M. The concepts and principles of equity and health. Int J Health Serv 1992, 22(3):429-445. 10.2190/986L-LHQ6-2VTE-YRRN, 1644507.
3. Marmot M. Social determinants of health inequalities. Lancet 2005, 365(9464):1099-1104.
4. Daniels N. Just Health. Meeting health needs fairly 2008, Cambridge: Cambridge University Press.
5. Acharya T, Daar AS, Dowdeswell E, Singer P, Thorsteinsdottir H. Genomics and Global Health. 2004, 96. Toronto: The genomics working group of the science and technology task force of the United Nations Millenium Project.
6. United Nations Human Development Report 2001: Making New Technologies Work for Human Development. 2001, New York: United Nations, United Nations.
7. Halla T, Abdallah SD, Richard DS, Peter AS. Genomics?a global public good?. The Lancet 2003, 361(9361):891-892.
8. Daar AS, Thorsteinsdottir H, Martin DK, Smith AC, Nast S, Singer PA. Top ten biotechnologies for improving health in developing countries. Nat Genet 2002, 32(2):229-232. 10.1038/ng1002-229, 12355081.
9. Hedgecoe AM. Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Science Technology and Human Values 2003, 28:513-537.
10. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: The promise of personalized medicine. The AAPS Journal 2000, 2(1):29-41.
11. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429(6990):464-468. 10.1038/nature02626, 15164072.
12. Williams-Jones B, Corrigan OP. Rhetoric and hype: where's the 'ethics' in pharmacogenomics?. Am J Pharmacogenomics 2003, 3(6):375-383. 10.2165/00129785-200303060-00004, 14672518.
13. Pang T. Impact of pharmacogenomics on neglected diseases of the developing world. Am J Pharmacogenomics 2003, 3(6):393-398. 10.2165/00129785-200303060-00006, 14672520.
14. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nature Reviews Genetics 2005, 6(3):241-246.
15. Peterson-Iyer K. Pharmacogenomics, ethics, and public policy. Kennedy Institute of Ethics journal 2008, 18(1):35-56. 10.1353/ken.0.0004, 18561577.
16. Seguin B, Hardy BJ, Singer PA, Daar AS. Universal health care, genomic medicine and Thailand: investing in today and tomorrow. Nature reviews 2008, 9(Suppl 1):S14-19.
17. Seguin B, Hardy BJ, Singer PA, Daar AS. Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nature reviews 2008, 9(Suppl 1):S5-9.
18. Hardy BJ, Seguin B, Singer PA, Mukerji M, Brahmachari SK, Daar AS. From diversity to delivery: the case of the Indian Genome Variation initiative. Nature reviews 2008, 9(Suppl 1):S9-14.
19. Reich MR. The global drug gap. Science 2000, 287:1979-1981. 10.1126/science.287.5460.1979, 10755953.
20. Hale VG, Woo K, Lipton HL. Oxymoron No More: The Potential Of Nonprofit Drug Companies To Deliver On The Promise Of Medicines For The Developing World. 2005, 24(4):1057-1063.
21. The World Factbook. , https://www.cia.gov/library/publications/the-world-factbook/rankorder/2102rank.html#top
22. Faunce TA. Global Intellectual Protection for Innovative Pharmaceuticals: Challenges for Bioethics and Health Law. Globalisation and Health 2005, 87-108. Dordrecht: Springer, Bennet B, Tomossy GF.
23. Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J Biol Med 2002, 75(4):221-231. 2588790, 12784973.
24. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine 2001, 345(6):433-442. 10.1056/NEJM200108093450607, 11496855.
25. Clark DWJ, Layton D, Shakir SAW. Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?: Linking Pharmacology with Pharmacoepidemiology. Drug Safety 2004, 27(7):427-456. 10.2165/00002018-200427070-00002, 15141995.
26. Shastry BS. Pharmacogenetics and the concept of individualized medicine. The Pharmacogenomics Journal 2006, 6:16-21. 10.1038/sj.tpj.6500338, 16302022.
27. Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005, 14(Spec No. 2):R207-214.
28. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279(15):1200-1205. 10.1001/jama.279.15.1200, 9555760.
29. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. The Annals of pharmacotherapy 2008, 42(7):1017-1025. 10.1345/aph.1L037, 18594048.
30. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002, 24(2):46-54. 10.1023/A:1015570104121, 12061133.
31. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC clinical pharmacology 2007, 7:8. 1963321, 17662147.
32. Gu Q, Dillon CF, Burt VL. Prescription Drug Use Continues to Increase: U.S. Prescription Drug Data for 2007-2008. NCHS Data Brief 2010, (42).
33. Johnson A. Drug Firms See Poorer Nations as Sales Cure. Wall Street Journal 2009,
34. Greely HT. Pharmacogenomics: promise, prospects, and potential problems. Medical Ethics 2002, 9(1).
35. Cohen-Kohler JC. The morally uncomfortable global drug gap. Clinical pharmacology and therapeutics 2007, 82(5):610-614. 10.1038/sj.clpt.6100359, 17898710.
36. Basu P. International patent law-boon or bane of biotech?. Nature biotechnology 2005, 23(1):13-15. 10.1038/nbt0105-13, 15637604.
37. Maiga D, Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health policy (Amsterdam, Netherlands) 2010, 97(2-3):130-135.
38. Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health policy and planning 2001, 16(1):13-20. 10.1093/heapol/16.1.13, 11599664.
39. Carlson K, Glandon D. Tracking Household Health Expenditures in Developing Countries through Major Population-based Surveys. Health Systems 20/20 project 2009, Bethesda: USAID, Abt Associates I.
40. Garg CC, Karan AK. Reducing out-of-pocket expenditures to reduce poverty: a disaggregated analysis at rural-urban and state level in India. Health policy and planning 2009, 24(2):116-128. 10.1093/heapol/czn046, 19095685.
41. WHO Achieving Health Equity: from root causes to fair outcomes. 2004, Geneva: WHO, Health CoSDo, WHO.
42. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009, 373(9659):240-249. 10.1016/S0140-6736(08)61762-6, 19042012.
43. Russell S. The Economic Burden of Illness for Households in Developing Countries: A Review of Studies Focusing on Malaria, Tuberculosis, and human immunodeficiency Virus/Acquired Syndrome. Am J Trop Med Hyg 2004, 71(2_suppl):147-155.
44. Enemark U, Alban A, Seoane-Vasquez EC, Seiter A. Purchasing Pharmaceuticals. Spending Wisely: buying health services for the poor 2005, 251-266. Washington, D.C.: The World Bank, Preker AS, Langenbrunner JC.
45. Lu C, Schneider MT, Gubbins P, Leach-Kemon K, Jamison D, Murray CJ. Public financing of health in developing countries: a cross-national systematic analysis. Lancet 375(9723):1375-1387.
46. Anderies JM, Janssen MA, Ostrom E. A framework to analyze the robustness of social-ecological systems from an institutional perspective. Ecology and Society 2004, 9(1).
47. Hecht R, Wilson P, Palriwala A. Improving Health R&D Financing for Developing Countries: A Menu of Innovative Policy Options. Health Aff 2009, 28(4):974.
48. Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, Gardner CA, Gupta RK, Haycock J, Heher AD, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005, 309(5733):401-404. 10.1126/science.1115538, 16020723.
49. Lanjouw JO, MacLeod M. Statistical Trends in Pharmaceutical Research for Poor Countries. 2005, WHO, WHO.
50. Marshall A. Getting the right drug into the right patient. Nature Biotechnology 1997, 15:1249-1252.
51. Pang T. Impact of pharmacogenomics on neglected diseases of the developing world. Am J Pharmacogenomics 2003, 3(6):393-398. 10.2165/00129785-200303060-00006, 14672520.
52. Olivier C, Williams-Jones B, Godard B, Mikalson B, Ozdemir V. Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking Inequities in Patient Care and International Health. Current Pharmacogenomics and Personalized Medicine 2008, 6(2):108-120.
53. Crews M. Pharmacogenomics: Tailoring the Drug Approval Process for Designer Drugs. J Contemp Health L & Pol'y 2008, 24:363-398.
54. Bhutta ZA. Beyond informed consent. Bulletin of the World Health Organization 2004, 82(10):771-777. 2623030, 15643799.
55. Vallely A, Lees S, Shagi C, Kasindi S, Soteli S, Kavit N, Vallely L, McCormack S, Pool R, Hayes RJ. How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania. BMC medical ethics 11:10.
56. Caplan AL. Clinical trials of drugs and vaccines among the desperately poor in poor nations: ethical challenges and ethical solutions. Clinical pharmacology and therapeutics 88(5):583-584.
57. Ballantyne AJ. How to do research fairly in an unjust world. Am J Bioeth 10(6):26-35.
58. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. The New England journal of medicine 2009, 360(8):816-823. 10.1056/NEJMsb0803929, 19228627.
59. Emanuel EJ, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. The Journal of infectious diseases 2004, 189(5):930-937. 10.1086/381709, 14976611.
60. Weigmann K. Racial medicine: here to stay? The success of the International HapMap Project and other initiatives may help to overcome racial profiling in medicine, but old habits die hard. EMBO reports 2006, 7(3):246-249. 10.1038/sj.embor.7400654, 1456889, 16607392.
61. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. The New England journal of medicine 2004, 351(20):2049-2057. 10.1056/NEJMoa042934, 15533851.
62. Kahn J. Getting the numbers right: statistical mischief and racial profiling in heart failure research. Perspectives in biology and medicine 2003, 46(4):473-483. 10.1353/pbm.2003.0087, 14593217.
63. Kahn J, Sankar P. Being specific about race-specific medicine. Health affairs (Project Hope) 2006, 25(5):w375-377.
64. Brody H, Hunt LM. BiDil: assessing a race-based pharmaceutical. Annals of family medicine 2006, 4(6):556-560. 10.1370/afm.582, 1687161, 17148635.
65. Sankar P, Kahn J. BiDil: race medicine or race marketing?. Health affairs (Project Hope) 2005, (Suppl Web Exclusives):W5-455-463.
66. Lee SS. The ethical implications of stratifying by race in pharmacogenomics. Clinical pharmacology and therapeutics 2007, 81(1):122-125. 10.1038/sj.clpt.6100020, 17186010.
67. Jordan SR. Race, Medicine, and Social Justice: Pharmacogenetics, Diversity, and the Case of BiDil. Review of Policy Research 2008, 25(1):53-69.
68. Bibbins-Domingo K, Fernandez A. BiDil for heart failure in black patients. Ann Intern Med 2007, 147(3):214-215; author reply 215-216.
69. Burroughs VJ, Maxey RW, Crawley LM, Levy RA. Cultural and Genetic Diversity in America: The Need for Individualized Pharmaceutical Treatment. 2002, 32p. National Pharmaceutical Council and National Medical Association.
70. Lam TP. Strengths and weaknesses of traditional Chinese medicine and Western medicine in the eyes of some Hong Kong Chinese. Journal of epidemiology and community health 2001, 55(10):762-765. 10.1136/jech.55.10.762, 1731793, 11553662.
71. Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Medical care 2002, 40(4):353-358. 10.1097/00005650-200204000-00011, 12021691.
72. Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M. Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Social science & medicine (1982) 2004, 59(6):1307-1313. 10.1016/j.socscimed.2004.01.009, 21874582.
73. UNAIDS Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. 2010, 364. UNAIDS, UNAIDS.
74. Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian journal of dermatology, venereology and leprology 2008, 74(3):234-237. 10.4103/0378-6323.41368, 18583790.
75. Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antiviral therapy 2007, 12(7):999-1013.
76. Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 2004, 5(5):479-486. 10.1517/14622416.5.5.479, 15212584.
77. The portal for rare diseases and orphan drugs. , http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=10&Disease_Disease_Search_dise aseGroup=Crohn-disease&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group of diseases=Crohn-disease&title=Crohn-disease&search=Disease_Search_Simple
78. Hulot JS. Pharmacogenomics and personalized medicine: lost in translation?. Genome medicine 2010, 2(2):13. 10.1186/gm134, 2847704, 20236491.
79. Altshuler D, Brooks LD, Chakravarti A, Collis FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005, 437(7063):1299-1320. 10.1038/nature04226, 1880871, 16255080.
80. Zhang W, Ratain MJ, Dolan ME. The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights 2008, 2:15-23. 2288550,2288550, 18392109.
81. Chen J, Teo YY, Toh DS, Sung C. Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments. Pharmacogenomics 2010, 11(8):1077-1094. 10.2217/pgs.10.79, 20712526.
82. Armengol L, Villatoro S, Gonzalez JR, Pantano L, Garcia-Aragones M, Rabionet R, Caceres M, Estivill X. Identification of copy number variants defining genomic differences among major human groups. PloS one 2009, 4(9):e7230. 10.1371/journal.pone.0007230, 2747275, 19789632.
83. Andiappan AK, Anantharaman R, Nilkanth PP, Wang de Y, Chew FT. Evaluating the transferability of Hapmap SNPs to a Singapore Chinese population. BMC genetics 2010, 11:36. 2877651, 20459637.
84. Montgomery SB, Sammeth M, Gutierrez-Arcelus M, Lach RP, Ingle C, Nisbett J, Guigo R, Dermitzakis ET. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature 2010, 464(7289):773-777. 10.1038/nature08903, 20220756.
85. Zhang W, Dolan ME. Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics 2010, 11(2):249-256. 10.2217/pgs.09.173, 2833269, 20136363.
86. Seguin B, Hardy BJ, Singer PA, Daar AS. Genomic medicine and developing countries: creating a room of their own. Nature reviews 2008, 9(6):487-493. 10.1038/nrg2379, 18487990.
87. Acharya T, Kumar NK, Muthuswamy V, Daar AS, Singer PA. "Harnessing genomics to improve health in India" - an executive course to support genomics policy. Health research policy and systems/BioMed Central 2004, 2(1):1. 434533, 15151698.
88. Ohashi W, Tanaka H. Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events. J Med Syst 34(4):701-707.
89. Nyika A. Ethical and practical challenges surrounding genetic and genomic research in developing countries. Acta Tropica 2009, 112(Supplement 1):S21-S31.
90. Daniels N, Kennedy BP, Kawachi I. Why justice is good for our health: the social determinants of health inequalities. Daedalus 1999, 128(4):215-251.
91. Kawachi I, Daniels N, Robinson DE. Health disparities by race and class: why both matter. Health affairs (Project Hope) 2005, 24(2):343-352.
92. Daniels N. Equity and Population Health: Toward a Broader Bioethics Agenda. Hastings Center Report 2006, 36(4):22-35. 10.1353/hcr.2006.0058, 17278869.
93. Marmot M, Friel S. Global health equity: evidence for action on the social determinants of health. Journal of epidemiology and community health 2008, 62(12):1095-1097. 10.1136/jech.2008.081695, 19008370.
94. Patouillard E, Hanson KG, Goodman CA. Retail sector distribution chains for malaria treatment in the developing world: a review of the literature. Malaria journal 2010, 9:50. 10.1186/1475-2875-9-50, 2836367, 20149246.
95. Woo J, Kwok T, Sze FKH, Yuan HJ. Ageing in China: health and social consequences and responses. International Journal of Epidemiology 2002, 31(4):772-775. 10.1093/ije/31.4.772, 12177017.
96. Gilchrist A, Bowles M, Wetherell M. Identities and Social Action: Connecting Communities for a Change. 2010, Economic & Social Research Council.
97. Du Toit P. "Parity of Esteem": A Conceptual Framework for Assessing Peace Processes, with a South African Case Study. International Journal of Comparative Sociology 2004, 45(3-4):195-212.
98. Mills EJ, Singh S, Nelson BD, Nachega JB. The impact of conflict on HIV/AIDS in sub-Saharan Africa. Int J STD AIDS 2006, 17(11):713-717. 10.1258/095646206778691077, 17062170.
99. Gordon P, Jacobson R, Porteous T. A study to establish the connections between HIV/AIDS & conflict. 2004, 74. John Snow International (UK).
100. Stabinski L, Pelley K, Jacob S, Long J, Leaning J. Reframing HIV and AIDS. British Medical Journal 2003, 327:1101-1103. 10.1136/bmj.327.7423.1101, 261752, 14604936.
101. International Monetary Fund. Data and statistics. , http://www.imf.org/external/data.htm
102. The World Bank. Data. , http://data.worldbank.org/